Literature DB >> 24319265

Immunization with a recombinant bacillus Calmette-Guerin strain confers protective Th1 immunity against the human metapneumovirus.

Christian E Palavecino1, Pablo F Céspedes, Roberto S Gómez, Alexis M Kalergis, Susan M Bueno.   

Abstract

Along with the human respiratory syncytial virus (hRSV), the human metapneumovirus (hMPV) is one of the leading causes of childhood hospitalization and a major health burden worldwide. Unfortunately, owing to an inefficient immunological memory, hMPV infection provides limited immune protection against reinfection. Furthermore, hMPV can induce an inadequate Th2 type immune response that causes severe lung inflammation, leading to airway obstruction. Similar to hRSV, it is likely that an effective clearance of hMPV would require a balanced Th1 type immunity by the host, involving the activation of IFN-γ-secreting T cells. A recognized inducer of Th1 immunity is Mycobacterium bovis bacillus Calmette-Guérin (BCG), which has been used in newborns for many decades and in several countries as a tuberculosis vaccine. We have previously shown that immunization with BCG strains expressing hRSV Ags can induce an efficient immune response that protects against this virus. In this study, we show that immunization with rBCG strains expressing the phosphoprotein from hMPV also can induce protective Th1 immunity. Mice immunized with rBCG were protected against weight loss, airway inflammation, and viral replication in the lungs after hMPV infection. Our rBCG vaccine also induced the activation of hMPV-specific T cells producing IFN-γ and IL-2, which could protect from hMPV infection when transferred to recipient mice. These data strongly support the notion that rBCG induces protective Th1 immunity and could be considered as an efficient vaccine against hMPV.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24319265     DOI: 10.4049/jimmunol.1300118

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  24 in total

Review 1.  Recent vaccine development for human metapneumovirus.

Authors:  J Ren; T Phan; X Bao
Journal:  J Gen Virol       Date:  2015-02-09       Impact factor: 3.891

2.  Dietary effect on immunological energetics in mice.

Authors:  Sebastián I Martel; Sebastián A Riquelme; Alexis M Kalergis; Francisco Bozinovic
Journal:  J Comp Physiol B       Date:  2014-08-17       Impact factor: 2.200

Review 3.  Modulation of Host Immunity by the Human Metapneumovirus.

Authors:  Pablo F Céspedes; Christian E Palavecino; Alexis M Kalergis; Susan M Bueno
Journal:  Clin Microbiol Rev       Date:  2016-10       Impact factor: 26.132

4.  Assessment of recombinant plasmid expressing fusion antigen Ag85B-Rv3425 in management of acute tuberculosis infection in mice.

Authors:  Huichang Huang; Feifei Wang; Enzhuo Yang; Honghai Wang; Peng Gao; Hongbo Shen
Journal:  Exp Ther Med       Date:  2018-01-23       Impact factor: 2.447

Review 5.  Aberrant T cell immunity triggered by human Respiratory Syncytial Virus and human Metapneumovirus infection.

Authors:  Andrea E González; Margarita K Lay; Evelyn L Jara; Janyra A Espinoza; Roberto S Gómez; Jorge Soto; Claudia A Rivera; Katia Abarca; Susan M Bueno; Claudia A Riedel; Alexis M Kalergis
Journal:  Virulence       Date:  2016-12-02       Impact factor: 5.882

Review 6.  Applications of bacillus Calmette-Guerin and recombinant bacillus Calmette-Guerin in vaccine development and tumor immunotherapy.

Authors:  Yuan-qiang Zheng; Youssef W Naguib; Yixuan Dong; Yan-chun Shi; Shorgan Bou; Zhengrong Cui
Journal:  Expert Rev Vaccines       Date:  2015       Impact factor: 5.217

7.  A Recombinant BCG Vaccine Is Safe and Immunogenic in Neonatal Calves and Reduces the Clinical Disease Caused by the Respiratory Syncytial Virus.

Authors:  Fabián E Díaz; Mariana Guerra-Maupome; Paiton O McDonald; Daniela Rivera-Pérez; Alexis M Kalergis; Jodi L McGill
Journal:  Front Immunol       Date:  2021-04-26       Impact factor: 7.561

Review 8.  Immune Response to Human Metapneumovirus Infection: What We Have Learned from the Mouse Model.

Authors:  Nagarjuna R Cheemarla; Antonieta Guerrero-Plata
Journal:  Pathogens       Date:  2015-09-18

9.  Human metapneumovirus in the preterm neonate: current perspectives.

Authors:  Nathalie L Maitre; John V Williams
Journal:  Res Rep Neonatol       Date:  2016-07-28

10.  Induction of Protective Immunity by a Single Low Dose of a Master Cell Bank cGMP-rBCG-P Vaccine Against the Human Metapneumovirus in Mice.

Authors:  Jorge A Soto; Nicolás M S Gálvez; Gaspar A Pacheco; Gisela Canedo-Marroquín; Susan M Bueno; Alexis M Kalergis
Journal:  Front Cell Infect Microbiol       Date:  2021-06-29       Impact factor: 5.293

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.